Renaissance Technologies LLC Makes New Investment in Senseonics Holdings, Inc. (NYSE:SENS)

Renaissance Technologies LLC purchased a new stake in shares of Senseonics Holdings, Inc. (NYSE:SENS) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,376,020 shares of the company’s stock, valued at approximately $720,000. Renaissance Technologies LLC owned about 0.23% of Senseonics as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Raymond James Financial Inc. acquired a new stake in shares of Senseonics during the fourth quarter worth about $26,000. HighTower Advisors LLC acquired a new stake in Senseonics in the 4th quarter worth about $32,000. Ridgecrest Wealth Partners LLC bought a new stake in Senseonics during the fourth quarter worth about $60,000. Virtu Financial LLC acquired a new position in shares of Senseonics during the 4th quarter worth $148,000. Finally, Charles Schwab Investment Management Inc. boosted its position in Senseonics by 9.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,339,698 shares of the company’s stock valued at $1,748,000 after buying an additional 274,842 shares in the last quarter. Institutional investors own 12.36% of the company’s stock.

Senseonics Price Performance

NYSE SENS opened at $0.72 on Friday. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. Senseonics Holdings, Inc. has a one year low of $0.25 and a one year high of $1.40. The company has a market capitalization of $473.06 million, a price-to-earnings ratio of -5.56 and a beta of 0.84. The stock has a 50-day moving average of $0.67 and a 200 day moving average of $0.61.

Senseonics (NYSE:SENS) last posted its earnings results on Monday, March 3rd. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.09). Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. During the same period in the previous year, the company earned ($0.07) earnings per share. On average, sell-side analysts forecast that Senseonics Holdings, Inc. will post -0.14 EPS for the current year.

Analyst Upgrades and Downgrades

SENS has been the subject of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of Senseonics in a research report on Wednesday, March 5th. Mizuho started coverage on shares of Senseonics in a report on Thursday, April 10th. They set an “outperform” rating and a $2.00 price objective on the stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.